Inoviq Ltd (AU:IIQ) has released an update.
INOVIQ Ltd has announced the successful validation of its NEURO-NET technology for isolating brain-derived exosomes from Parkinson’s Disease patients, a breakthrough that could lead to the development of early detection blood tests for the disease. By identifying a unique protein fingerprint in these exosomes, the technology has demonstrated potential for earlier diagnosis and improved treatment selection for both Alzheimer’s and Parkinson’s Diseases. The company is now pursuing further clinical validation and partnerships to advance diagnostics for a range of neurological conditions.
For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.
